2C-B

Template:Short description Template:Distinguish Template:Cs1 config Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=101412COc1cc(CCN)c(OC)cc1Br1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3YMHOBZXQZVXHBM-UHFFFAOYSA-N | _combo_data= | _physiological_data= | _clinical_data= Oral, insufflation<ref name="PiHKAL" /><ref name="Cole_2002" /><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Dean_2013" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="MallaroniMasonVinckenbosch2022" />Erox; Nexus; PerfomaxSerotonin receptor modulator; Serotonin 5-HT_2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Stimulant; EntactogenNone | _legal_data=Schedule 9F2Schedule IIIAnlage IClass AP IISchedule I

| _other_data=2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine

| _image_0_or_2 = 2C-B.svg4-bromo-2,5-dimethoxyphenethylamine (2C-B).png | _image_LR =

| _datapage = 2C-B (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=Schedule 9F2Schedule IIIClass ASchedule IP II | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=66142-81-2 | PubChem=98527 | ChemSpiderID=88978 | ChEBI=189669 | ChEMBL=292821 | DrugBank=DB01537 | KEGG=C22775 | _hasInChI_or_Key={{#if:1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3YMHOBZXQZVXHBM-UHFFFAOYSA-N |yes}} | UNII=V77772N32H | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields= |verifiedrevid=}} 2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families.<ref name="Cole_2002">Template:Cite journal</ref><ref name="Nugterenvan_Lonkhuyzen_2015">Template:Cite journal</ref><ref name="Wills_2012" /><ref name="Anilanmert_2018" /> It is a synthetic analogue of mescaline.<ref name="Anilanmert_2018">Template:Cite book</ref><ref name="Vari_2019">Template:Cite journal</ref><ref name="PiHKAL" /> The drug is used as a recreational drug and is usually taken orally.<ref name="PiHKAL" /> 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects.<ref name="PiHKAL" /><ref name="Wills_2012" /><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Luethi_2020">Template:Cite journal</ref><ref name="Gonzalez_2015">Template:Cite journal</ref><ref name="Oeri_2021">Template:Cite journal</ref><ref name="Shulgin_1975" /> Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin.<ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Palamar_2020" /><ref name="Mallaroni_2023" /><ref name="Shulgin_1975" />

The drug acts as a potent partial agonist of the serotonin 5-HT₂ receptors, including of the serotonin 5-HT_2A receptor.<ref name="Wallach_2023" /><ref name="Rickli_2015" /><ref name="Ray_2010" /> It produces psychedelic-like effects in animals.<ref name="Wallach_2023" /> Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013" /><ref name="Duan_2024" />

2C-B was developed by Alexander Shulgin in 1974<ref name="PoulieJensenHalberstadt2020" /><ref name="Dean_2013" /><ref name="Wills_2012" /> and was described by him in the scientific literature in 1975.<ref name="PassieBrandt2018">Template:Cite journal</ref><ref name="Shulgin_1975" /> It was legitimately marketed under the brand name Erox as an over-the-counter sexual enhancer in some European countries in the 1980s and early 1990s.<ref name="DOJ2006" /><ref name="Anilanmert_2018" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Johnson_2018" /> The drug also emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s.<ref name="Dean_2013" /><ref name="Wills_2012" /><ref name="Anilanmert_2018" /><ref name="Johnson_2018" /> Subsequently, it became a controlled substance in the United States in the mid-1990s.<ref name="Dean_2013" /><ref name="Wills_2012" /><ref name="Anilanmert_2018" /> 2C-B was one of the first 2C psychedelics to be described.<ref name="Dean_2013" /><ref name="Wills_2012" /><ref name="Shulgin_1975" /> It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.<ref name="Wills_2012" /><ref name="Anilanmert_2018" /><ref name="Palamar_2020" /><ref name="Gonzalez_2015" /><ref name="MallaroniMasonVinckenbosch2022" />

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2C-B's dose range as 12 to 24Template:Nbspmg orally and its duration as 4 to 8Template:Nbsphours.<ref name="PiHKAL">Template:CitePiHKAL https://www.erowid.org/library/books_online/pihkal/pihkal020.shtml</ref><ref name="JacobShulgin1994">Template:Cite book</ref><ref name="Shulgin2003">Template:Cite book</ref> However, in an earlier report, he described an effective dose range of 8 to 10Template:Nbspmg orally and a duration of 6 to 8Template:Nbsphours.<ref name="Shulgin_1975" /><ref name="Caudevilla-GálligoRibaVentura2012" /> Threshold effects occur at a dose of 4Template:Nbspmg orally.<ref name="Shulgin_1975" /><ref name="IversenIversenSnyder1978">Template:Cite book</ref> A wider recreational dose range of 2 to 55Template:Nbspmg or more orally has been described as well, with a typical dose estimate of about 20Template:Nbspmg.<ref name="LuethiLiechti2018">Template:Cite journal</ref><ref name="HalberstadtChathaKleinWallach2020">Template:Cite journal</ref><ref name="Cole_2002" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Gonzalez_2015" /><ref name="Mallaroni_2023" /><ref name="MallaroniMasonVinckenbosch2022" /> A low dose has been said to be 5 to 15Template:Nbspmg, a moderate dose 10 to 25Template:Nbspmg, and a high or strong dose 20 to 50Template:Nbspmg.<ref name="Cole_2002" /><ref name="Papaseit_2018" /><ref name="Nugterenvan_Lonkhuyzen_2015" /> Most people use doses of 20Template:Nbspmg or lower.<ref name="Caudevilla-GálligoRibaVentura2012" /> Shulgin and others describe 2C-B as having a steep dose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects.<ref name="PiHKAL" /><ref name="Palamar_2020" /><ref name="IversenIversenSnyder1978" /> Over the 12 to 24Template:Nbspmg dose range, every 2Template:Nbspmg increment can result in a profound increase or change in effects.<ref name="PiHKAL" /> Higher doses are said to lead to more intense but not longer-lasting effects.<ref name="IversenIversenSnyder1978" /> The drug's onset is about 1.2Template:Nbsphours, with a range of 0.3 to 1.5Template:Nbsphours, and its time to peak effects is about 2.5Template:Nbsphours on average.<ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Cole_2002" /><ref name="SpoelderLouwerensKrens2019" /> Effects on average last about 6Template:Nbsphours and are slightly shorter than those of psilocybin.<ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /> In addition to oral administration, 2C-B may be insufflated less commonly, with doses being approximately one-third of those of the oral route or in the range of 10 to 30Template:Nbspmg and with this route producing more rapid and intense of effects.<ref name="Cole_2002" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="MallaroniMasonVinckenbosch2022" />

The effects of 2C-B were reported by Shulgin to include sensory enhancement, brightened colors, visual richness, mental imagery, psychedelic visuals including kaleidoscopic and organic forms, sound distortion, increased appreciation of art and music, passivity, relaxation, emotional changes, euphoria, increased body awareness, tactile enhancement, feeling like waves of energy are flowing through oneself, feeling like one's body is flooded with orgasms, and sexual enhancement.<ref name="PiHKAL" /><ref name="Shulgin_1975" /><ref name="ShulginShulginJacob1986">Template:Cite journal</ref><ref name="Shulgin2003b">Template:Cite web</ref> He has succinctly described 2C-B as having "a luxury of sensory enhancement (visual, sexual, gustatory) with a minimum of introspective demands".<ref name="Shulgin_1983">Template:Cite book</ref> The drug was one of his favorite psychedelics.<ref name="Shulgin2003b" /> At doses of 8 to 10Template:Nbspmg, 2C-B was described as consistently producing substantial sensory enhancement, but as not "superimposing hallucinogenesis" or as having "no hallucinogenic effects", with the state being described as quite distinct from that usually associated with psychedelics.<ref name="Shulgin_1975" /><ref name="Caudevilla-GálligoRibaVentura2012" /> It was also said to lack the lassitude that can be associated with psilocybin.<ref name="Shulgin_1975" />

In published reports by other authors, 2C-B has been claimed to produce effects including visual, auditory, and tactile perceptual changes, closed-eye imagery, LSD-like visuals such as colors and geometric shapes, time dilation, MDMA-like stimulant and entactogenic effects, such as being more in touch with emotions, as well as feelings of love, enhanced sociability, and empathy, feelings of peace and well-being, euphoria, a "body high", increased sensitivity to touch, touch feeling pleasurable, and being erotic.<ref name="Palamar_2020" /><ref name="MallaroniMasonVinckenbosch2022" /><ref name="SextonNicholsHendricks2019" /><ref name="Caudevilla-GálligoRibaVentura2012" /> The presence of entactogenic effects with 2C-B is said to be unique among most psychedelics, along with certain other atypical psychedelics like 5-MeO-DiPT and 5-MeO-MiPT.<ref name="Luethi_2020" /><ref name="Oeri_2021" /><ref name="Gonzalez_2015" /><ref name="Palamar_2020" /> 2C-B's effects are often described as being milder and more easily managed than other psychedelics.<ref name="Palamar_2020">Template:Cite journal</ref><ref name="MallaroniMasonVinckenbosch2022">Template:Cite journal</ref><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Nugterenvan_Lonkhuyzen_2015" /> For example, it is said to be less incapacitating or impairing, "non-ego-threatening", not "mentally challenging" or confusing, not leading to an "extreme headspace", and leaving the mind "very clear".<ref name="Palamar_2020" /><ref name="Caudevilla-GálligoRibaVentura2012" /> In addition, it is said to produce changes in thought and time perception less frequently.<ref name="Caudevilla-GálligoRibaVentura2012" /> Due to its potential for relatively light effects, the drug has been referred to as the "Diet Coke of psychedelics" or as a "beginner psychedelic".<ref name="Palamar_2020" /> Nonetheless, it has been described as quite visual, with the potential for all of the visuals of LSD but without the head space that LSD and psilocybin produce.<ref name="Palamar_2020" /> However, the visuals are dose-dependent, being mild at lower doses and being more substantial and LSD-like at higher doses.<ref name="Palamar_2020" /> 2C-B is often compared to a mixture of LSD and MDMA or a "candyflip".<ref name="Palamar_2020" /><ref name="Caudevilla-GálligoRibaVentura2012" /> However, it is described as a "clear-headed candyflip", with entactogenic-like effects, LSD-like effects such as visuals, but a very clear head space.<ref name="Palamar_2020" /> In addition, it is said to not have the same kind of forceful positive mood push that MDMA has, and to be a little more unpredictable and capable of causing bad trips or negative head spaces.<ref name="Palamar_2020" /> 2C-B is said to be more of a "party drug", to be more recreational, and to have less likelihood of challenging, emotional-breakthrough, or mystical-type experiences, relative to psychedelics like psilocybin and LSD.<ref name="SextonNicholsHendricks2019" /><ref name="Caudevilla-GálligoRibaVentura2012" />

Formal clinical studies have found that 2C-B produces a mixture of psychedelic, some possible entactogen-like, and some stimulant effects.<ref name="Gonzalez_2015" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023">Template:Cite journal</ref> Specific effects in these studies have included slight hallucinogenic states, perceptual changes, ego dissolution, time dilation, increased creativity, stimulation, vigor, happiness or elation, euphoria, feelings of well-being, reduced anger, enhanced sociability and friendliness, increased reactivity to negative emotional stimuli, decreased ability to recognize expressions of happiness, augmented emotionality in speech, tenseness, confusion, and mild sympathomimetic effects such as pressor effects, among others.<ref name="Gonzalez_2015" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /> Findings on the entactogen-like effects of 2C-B have been mixed, with some studies reporting that it produces such effects<ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Gonzalez_2015" /> but other studies finding no such effects similarly to psilocybin.<ref name="Mallaroni_2023" /> However, in other research, both psilocybin and MDMA have been found to increase emotional empathy.<ref name="Mallaroni_2023" /> Compared to psilocybin in a double-blind, placebo-controlled clinical trial, 2C-B produced fewer negative mood effects, greater positive mood effects, less intense hallucinogenic effects including overall altered consciousness, oceanic boundlessness, ego dissolution, experiential depth, and time dilation, and less cognitive impairment.<ref name="Mallaroni_2023" /> Conversely, their effects in terms of visual changes and enhanced body perception were equivalent.<ref name="Mallaroni_2023" /> Besides having more positively valenced mood effects than psilocybin, 2C-B produced MDMA-like positive mood effects with little in the way of negative mood effects.<ref name="Mallaroni_2023" /> It was concluded that in line with anecdotal reports, 2C-B is non-ego-threatening, lacks the more serious head space of other psychedelics, and has a greater emphasis on visual and tactile changes.<ref name="Mallaroni_2023" /> It was also remarked that 2C-B may be a more optimal psychedelic for people afraid of the psychedelic experience or at greater risk for negative experiences such as due to high neuroticism, with this applicable for instance in the context of psychedelic-assisted psychotherapy.<ref name="Mallaroni_2023" />

2C-B tablets often contain a dose of 5 or 10Template:Nbspmg of the drug.<ref name="Cole_2002" /><ref name="Papaseit_2018" /> Low doses of 2C-B like 5 to 10Template:Nbspmg orally are said to produce stimulation, entactogen-like effects, and perceptual enhancement, while higher doses like 10 to 20Template:Nbspmg orally are said to produce psychedelic and hallucinogenic effects.<ref name="SpoelderLouwerensKrens2019" /><ref name="deBoerGijzelsBosman1999">Template:Cite journal</ref><ref name="Wills_2012" /><ref name="Nugterenvan_Lonkhuyzen_2015" /> 2C-B is frequently used at low doses as a substitute for MDMA.<ref name="SextonNicholsHendricks2019">Template:Cite journal</ref> It is often used by people who go to electronic music festivals, also known as raves.<ref name="SextonNicholsHendricks2019" /><ref name="MallaroniMasonVinckenbosch2022" /> The drug is also frequently used at clubs and parties, at home, or in nature.<ref name="Caudevilla-GálligoRibaVentura2012" /> 2C-B is often combined with other drugs, such as MDMA, alcohol, and cannabis.<ref name="Caudevilla-GálligoRibaVentura2012" /> Besides recreational use, 2C-B has been used in psychedelic-assisted psychotherapy at doses of 15 to 30Template:Nbspmg orally.<ref name="SessaFischer2016">Template:Cite journal</ref>

Side effects

The adverse effects of 2C-B have been studied.<ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Gonzalez_2015" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /> They have been reported to include difficulty focusing gaze, trembling, sweating, nausea, abdominal pain, tachycardia, jaw clenching, difficulty breathing, coughing, diarrhea, dizziness, muscle or joint pain, tenseness, confusion, psychomotor slowing, and spatial memory impairment, among others.<ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /> Autonomic or sympathomimetic side effects include slightly increased heart rate and blood pressure and are lower than the increases with amphetamines and MDMA but similar to those with psilocybin.<ref name="Gonzalez_2015" /><ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /> It produces a slight increase in cortisol levels that is also much lower than the marked increases observed with other psychedelics and MDMA.<ref name="Papaseit_2018" /> Hyperthermia has been reported at high doses.<ref name="Papaseit_2018" /> Residual side effects of 2C-B have been reported to include insomnia, flashbacks, anxiety, coughing, difficulty concentrating, and depression or sadness, among others.<ref name="Caudevilla-GálligoRibaVentura2012" />

Severe adverse reactions are rare, but use of 2C-B was linked to significant brain injury in one case report; the alleged "2C-B" was never actually discovered by testing so the only evidence suggesting 2C-B was the cause was the victim's own words, without taking into consideration that adulteration and impurities are very common in illicit drugs.<ref name="Ambrose_2010">Template:Cite journal</ref> In a later case report of unknown dose, 2C-B caused serotonin syndrome, seizures, severe brain edema, and severe and long-lasting neurological impairment.<ref name="SpoelderLouwerensKrens2019">Template:Cite journal</ref> There is a case report of acquired synesthesia following a single very high dose of 2C-B.<ref name="Yanakieva_2019">Template:Cite journal</ref> There is also a case report of persistent psychosis following a single dose of 2C-B.<ref name="Huang_2011">Template:Cite journal</ref>

2C-B is a potent serotonin 5-HT_2B receptor agonist similarly to many other serotonergic psychedelics and hence may pose a risk of cardiac valvulopathy and other complications with frequent long-term use.<ref name="LuethiLiechti2021">Template:Cite book</ref><ref name="McIntyre2023">Template:Cite journal</ref><ref name="RouaudCalderHasler2024">Template:Cite journal</ref><ref name="Wsół2023">Template:Cite journal</ref><ref name="TagenMantuanivanHeerden2023">Template:Cite journal</ref>

Overdose

At doses over 20 or 30Template:Nbspmg orally, frightening hallucinations, as well as tachycardia, hypertension, and hyperthermia, may occur.<ref name="Carmo_2005">Template:Cite journal</ref><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="PiHKAL" /> The lethal dose is unknown. It was reported by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) that a psychologist had accidentally taken a 100Template:Nbspmg dose orally without apparent harm.<ref name="PiHKAL" /> There are three case reports of 2C-B intoxication in the scientific literature as of 2015 and no deaths have been attributed to 2C-B alone as of 2018.<ref name="Papaseit_2018" /><ref name="Nugterenvan_Lonkhuyzen_2015" />

Interactions

2C-B is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B.<ref name="Dean_2013">Template:Cite journal</ref><ref name="Theobald_2007">Template:Cite journal</ref> Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-B.<ref name="Dean_2013" /><ref name="Theobald_2007" /><ref name="Halman_2024">Template:Cite journal</ref> This may result in overdose and serious toxicity.<ref name="Halman_2024" /><ref name="Dean_2013" /> 2C-B may also have interactions with other medications and drugs.<ref name="Inan_2020" />

Pharmacology

Pharmacodynamics

Template:Nowrap

Target	Affinity (Ki, nM)
5-HT1A	130–311
5-HT1B	104
5-HT1D	26
5-HT1E	120
5-HT1F	Template:Abbr
5-HT2A	0.66–32 (Ki) 1.20–689 (Template:Abbrlink) 4–101% (Template:Abbrlink)
5-HT2B	13.5–97 (Ki) 12.6–130 (Template:Abbr) 52–97% (Template:Abbr)
5-HT2C	32–90 (Ki) 0.03–493 (Template:Abbr) 50–116% (Template:Abbr)
5-HT3	>10,000
5-HT4	Template:Abbr
5-HT5A	>10,000
5-HT6	320
5-HT7	210
α1A	>10,000
α1B	>10,000
α1D	Template:Abbr
α2A	309–320
α2B	>10,000
α2C	103
β1	>10,000
β2	>10,000
β3	Template:Abbr
D1	12,000
D2	2,200–25,200
D3	7,116–10,000
D4	>10,000
D5	>10,000
H1–H4	>10,000
M1–M2	>10,000
M3	822
M4–M5	>10,000
I1	2,155
σ1	>10,000
σ2	>10,000
Template:Abbrlink	90–3,000 (Ki) (rodent) 3,300–7,190 (Template:Abbr) (human)
Template:Abbrlink	9,700–13,300 (Ki) 18,000–312,900 (Template:Abbrlink)
Template:Abbrlink	27,400–31,000 (Ki) 44,000–122,000 (Template:Abbr)
Template:Abbrlink	6,500–>30,000 (Ki) 132,000–231,000 (Template:Abbr)
Template:Abbrlink	125,000 (Template:Abbr)
Template:Abbrlink	58,000 (Template:Abbr)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: <ref name="PDSPKiDatabase">Template:Cite web</ref><ref name="BindingDB">Template:Cite web</ref><ref name="Ray_2010">Template:Cite journal</ref><ref name="Rickli_2015">Template:Cite journal</ref><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Wallach_2023">Template:Cite journal</ref> <ref name="MarcherRrsted_2020">Template:Cite journal</ref><ref name="Luethi_2018">Template:Cite journal</ref><ref name="Rudin_2022">Template:Cite journal</ref><ref name="Pottie_2020" /><ref name="AcunaCastillo_2002">Template:Cite journal</ref><ref name="Flanagan_2021">Template:Cite journal</ref><ref name="Wagmann_2019">Template:Cite journal</ref><ref name="Zwartsen_2017">Template:Cite journal</ref><ref name="Simmler_2016">Template:Cite journal</ref>

2C-B acts as a potent partial agonist of the serotonin 5-HT₂ receptors, including of the serotonin 5-HT_2A and 5-HT_2C receptors and to a lesser extent of the serotonin 5-HT_2B receptor.<ref name="Wallach_2023" /><ref name="Rickli_2015" /><ref name="Ray_2010" /> In one study, it had Template:Abbrlink (Template:Abbrlink) values of 1.2Template:NbspnM (101%) at the serotonin 5-HT_2A receptor, 13Template:NbspnM (97%) at the serotonin 5-HT_2B receptor, and 0.63Template:NbspnM (98%) at the serotonin 5-HT_2C receptor.<ref name="Wallach_2023" /> In earlier studies, 2C-B was found to be a low-efficacy serotonin 5-HT_2A and 5-HT_2C receptor partial agonist or even antagonist.<ref name="Moya_2007">Template:Cite journal</ref><ref name="Villalobos_2004">Template:Cite journal</ref><ref name="Nugterenvan_Lonkhuyzen_2015" /> However, subsequent studies have consistently found higher efficacy of 2C-B at these receptors.<ref name="Wallach_2023" /><ref name="Rickli_2015" /><ref name="Ray_2010" /> In addition to the serotonin 5-HT₂ receptors, 2C-B also shows lower affinity for other serotonin receptors, such as the serotonin 5-HT_1A and 5-HT_1B receptors among others.<ref name="Ray_2010" /><ref name="Rickli_2015" /><ref name="Nugterenvan_Lonkhuyzen_2015" /> However, while 2C-B itself was not assessed, other 2C derivatives showed little activity as serotonin 5-HT_1A receptor agonists (Template:Abbr = >3,000Template:NbspnM).<ref name="Eshleman_2014" />

2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency.<ref name="SaezBriones_2019">Template:Cite journal</ref><ref name="Montgomery_2007">Template:Cite journal</ref><ref name="Potts_2022">Template:Cite book</ref><ref name="Canal_2018">Template:Cite journal</ref><ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Caudevilla-GálligoRibaVentura2012">Template:Cite journal</ref> Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine (Template:Abbr = >100,000Template:NbspnM or "inactive").<ref name="Nagai_2007">Template:Cite journal</ref><ref name="Eshleman_2014">Template:Cite journal</ref>

2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.<ref name="Wallach_2023" /> It also shows potent and efficacious anti-inflammatory effects in preclinical research.<ref name="FlanaganBillacLandry2021">Template:Cite journal</ref>

Pharmacokinetics

Absorption

2C-B appears to have relatively low oral bioavailability.<ref name="Mallaroni_2023" /> With 30Template:Nbspmg 2C-B by orally, its peak concentrations (mean ± SD) were 5.4Template:Nbspng/mL and its time to peak concentrations was 2.3Template:Nbsphours.<ref name="Thomann_2025" /> In another study, with 20Template:Nbspmg 2C-B orally, peak levels were 3.31Template:Nbspng/mL and time to peak levels was 2.43Template:Nbsphours.<ref name="Mallaroni_2023" />

Metabolism

2C-B appears to undergo substantial first-pass metabolism.<ref name="Mallaroni_2023" /> It has been shown to be metabolized by liver hepatocytes, resulting in deamination and demethylation that produces several products. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites. Additionally, 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) can be produced by oxidative deamination. Further metabolism of BDMPE and BDMPAA may occur by demethylation. Alternatively, the later metabolites can be generated by demethylation of 2C-B followed by oxidative deamination.<ref name="Carmo_2005" /> Deamination of 2C-B is mediated by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B.<ref name="Dean_2013" /><ref name="Theobald_2007" /><ref name="Thomann_2025" />

There is species differentiation in the metabolism of 2C-B.<ref name="Carmo_2005" /> Mice hepatocytes produce 4-bromo-2,5-dimethoxyphenol (BDMP), a previously unknown metabolite.<ref name="Carmo_2005" /> Meanwhile, human, monkey, and rabbit hepatocytes produce 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), but dog, rat, and mouse hepatocytes do not.<ref name="Carmo_2005" />

2C-B's metabolites BDMPAA and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in humans occur at peak concentrations 280-fold and 17-fold higher than those of 2C-B with oral administration of 2C-B, respectively.<ref name="Thomann_2025" />

Elimination

The elimination half-life of 2C-B in humans is 1.2 to 2.5Template:Nbsphours.<ref name="Papaseit_2018" /><ref name="Mallaroni_2023" /><ref name="Thomann_2025" />

Chemistry

2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine, is a substituted phenethylamine of the 2C family, also known as the 4-substituted 2,5-dimethoxyphenethylamines.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013" /> It is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline found in peyote and certain other cacti.<ref name="Anilanmert_2018" /><ref name="Vari_2019" /><ref name="PiHKAL" />

Synthesis

The chemical synthesis of 2C-B has been described.<ref name="PiHKAL" /><ref name="Shulgin_2011">Template:Cite book</ref><ref name="Shulgin_1975" />

Identification

Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.Template:Citation needed

Marquis	Mecke	Mandelin	Liebermann	Froehde	Robadope
Yellow to green	Yellow to olive brownish	green	Yellow to black	Yellow to green	Slow pink
Ehrlich	Hofmann	Simon's	Scott	Folin
No reaction	No reaction	No reaction	No reaction	(Light) purple

Analogues and derivatives

Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013">Template:Cite book</ref><ref name="Duan_2024" />

DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013" /> β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013" /> βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT_2A receptor agonist compared to 2C-B.<ref name="Pottie_2020">Template:Cite journal</ref>

A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B and N-benzyl-2C-B.<ref name="Glennon_1994" /> Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40Template:Nbsptimes lower affinity for the serotonin 5-HT_2A receptor.<ref name="Glennon_1994" /> The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly.<ref name="Glennon_1994">Template:Cite journal</ref> This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe,<ref>Template:Cite thesis</ref> and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B.<ref name="Trachsel_2013" /><ref name="Elliott_2020">Template:Cite journal</ref><ref name="Ponce_2024">Template:Cite journal</ref>

2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B.<ref name="Trachsel_2013" /> TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well.<ref name="PiHKAL" /><ref name="Shulgin_2003">Template:Cite book</ref><ref name="Jacob_1994">Template:Cite journal</ref><ref name="Trachsel_2013" /> ASR-2001 (2CB-5PrO) is a propoxy TWEETIO and another notable analogue of 2C-B which is under development for treatment of psychiatric disorders.<ref name="Busby_2023">Template:Cite web</ref><ref name="Busby_2025">Template:Cite web</ref><ref name="Kargbo_2025">Template:Cite journal</ref>

FLY derivatives of 2C-B like 2C-B-FLY, 2C-B-DRAGONFLY, and 2C-B-BUTTERFLY are analogues in which the methoxy groups of 2C-B on the phenyl ring have been cyclized into furan or other rings to form benzodifuran and other tricyclic compounds.<ref name="Shulgin_2011" /><ref name="Trachsel_2013" />

Cyclized phenethylamine derivatives of 2C-B in which the side chain has been cyclized in some way include DOB-CR (2C-B-CR), 2CB-Ind, 2C-B-5-hemiFLY-α6 (BNAP), 2CB7 (2C-B-5-hemiFLY-β7), TCB-2 (2CBCB), 2C-B-PYR, 2CBecca, 2CJP, 2CLisaB, ZC-B, 2C-B-aminorex, and 2C-B-morpholine, among others.<ref name="Trachsel_2013" /><ref name="Duan_2024">Template:Cite journal</ref><ref name="Nichols_2018">Template:Cite book</ref> Other related cyclized compounds, while not technically phenethylamines or 2C-B derivatives, include 2C-B-BZP and 2C-B-PP.<ref name="Trachsel_2013" /><ref name="Shulgin_2011" />

History

2C-B was first synthesized and evaluated by American chemist Alexander Shulgin in 1974.<ref name="PoulieJensenHalberstadt2020" /><ref name="Dean_2013" /><ref name="Wills_2012" /> He described the properties and effects of 2C-B in humans, along with those of 2C-D, in the scientific literature in 1975.<ref name="PassieBrandt2018" /><ref name="Wills_2012" /><ref name="PiHKAL" /><ref name="Shulgin_1975">Template:Cite journal</ref> Shulgin proposed 2C-B and 2C-D for use in psychedelic-assisted psychotherapy.<ref name="Shulgin_1975" /><ref name="Dean_2013" /> However, it was reportedly abandoned for such purposes due to gastrointestinal side effects and lack of entactogenic effects.<ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Dean_2013" />

2C-B was legitimately marketed and sold as an over-the-counter sexual enhancer under brand names like Erox in several European countries such as Germany in the 1980s and early 1990s.<ref name="PoulieJensenHalberstadt2020" /><ref name="DOJ2006">Template:Cite web</ref><ref name="Anilanmert_2018" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Johnson_2018">Template:Cite book</ref> It was manufactured by the German pharmaceutical company Drittewelle and was sold in adult stores, smart shops, and some nightclubs.<ref name="PoulieJensenHalberstadt2020">Template:Cite journal</ref><ref name="DOJ2006" /><ref name="Caudevilla-GálligoRibaVentura2012" /><ref name="Erowid2002">Template:Cite web</ref> In addition, 2C-B was sold in Dutch smart shops as an ecstasy-like legal high under names like Nexus.<ref name="PoulieJensenHalberstadt2020" /><ref name="Johnson_2018" /> 2C-B was first encountered as a novel recreational designer drug in the United States in 1985.<ref name="Wills_2012" /> It was advertised and used as an MDMA substitute after MDMA was made illegal around this time.<ref name="Dean_2013" /><ref name="Wills_2012">Template:Cite book</ref><ref name="Anilanmert_2018" />

2C-B has been said to have been legally sold in Southern Africa from 1993 to 1996 and used as an entheogen by the Sangoma, Nyanga, and Amagqirha people in place of their traditional plants; they refer to the chemical as Ubulawu Nomathotholo, which roughly translates to "Medicine of the Singing Ancestors".<ref>Template:Cite web</ref><ref>The Nexus Factor - An Introduction to 2C-B Erowid</ref><ref>Ubulawu Nomathotholo Pack Photo by Erowid. © 2002 Erowid.org</ref>

The drug became a controlled substance in the United States in 1994.<ref name="PoulieJensenHalberstadt2020" /><ref name="PoulieJensenHalberstadt2020" /><ref name="Dean_2013" /><ref name="Wills_2012" /><ref name="Anilanmert_2018" /> It also became a controlled substance in most other countries in the mid-1990s.<ref name="Caudevilla-GálligoRibaVentura2012" /> In addition, 2C-B was placed in Schedule II of the United Nations Convention on Psychotropic Substances and hence became an internationally controlled substance in 2001.<ref name="Nugterenvan_Lonkhuyzen_2015" /><ref name="Papaseit_2018" /> Following 2C-B's restriction, other 2C psychedelics emerged as designer drugs.<ref name="Dean_2013" /> Nonetheless, 2C-B is the most popular of the 2C psychedelics.<ref name="Wills_2012" /><ref name="Anilanmert_2018" /><ref name="Palamar_2020" /><ref name="MallaroniMasonVinckenbosch2022" /> Numerous other 2C drugs besides 2C-B have also been made controlled substances.<ref name="Anilanmert_2018" /> Besides other 2Cs, derivatives of 2C-B such as 2C-B-FLY and 25B-NBOMe have been developed and emerged as well-known novel designer drugs.<ref name="PiHKAL" /><ref name="Shulgin_2011" /><ref name="Trachsel_2013" />

Society and culture

Names

Brand names and street names of 2C-B include Nexus, Venus, Bromo, Erox, Perfomax, Bees, Toonies, Spectrum, XTC, and Synergy, among others.<ref name="Dean_2013" /><ref name="Wills_2012" /><ref name="Cole_2002" /><ref name="DEA - Evaluation Section">Template:Cite web</ref>

Illicit forms

A gram of 2C-B powder.

File:2cb pill.jpg

A 2C-B pill with heart logo.

Street purity of 2C-B, when tested, has been found to be relatively high.<ref name="Cole_2002" /> Researchers in Spain found that 2C-B samples in the country doubled between 2006 and 2009, switched from primarily powder form to tablets, and exhibited "low falsification rates".<ref name="Caudevilla-GálligoRibaVentura2012" /> An analysis of street samples in the Netherlands found impurities "in small percentages"; only one of the impurities, the N-acetyl derivative of 2C-B, could be identified, and comprised 1.3% of the sample. The authors suggested that this compound was a by-product of 2C-B synthesis.<ref name="deBoerGijzelsBosman1999" />

In 2011, street prices in the United States ranged between $10 and $30 per tablet when purchased in small quantities.<ref name="DEA - Evaluation Section" /> Larger retail purchases cost between $200 and $500 per gram. Wholesale purchases of 2C-B would lower the price ($100 to $300 per gram in 2001, $30 to $100 on the darknet in 2020).<ref name="Reappears">Template:Cite web</ref>

Legal status

United Nations

The UN Commission on Narcotic Drugs added 2C-B to Schedule II of the Convention on Psychotropic Substances in March 2001.<ref>Template:Cite web</ref>

2C-B is a scheduled drug in most jurisdictions.<ref>Template:Cite web</ref> The following is a partial list of territories where the substance has been scheduled.

Argentina

2C-B is controlled under the List 1, as well as similar substances like 2C-I or 2C-T-2.<ref>Template:Cite web</ref>

Australia

2C-B is controlled in Australia and on the list of substances subject to import and export controls (Appendix B). It was placed on Schedule One of the Drugs Misuse and Trafficking Act when it first came to notice in 1994, when in a showcase legal battle chemist R. Simpson was charged with manufacturing the substance in Sydney. Alexander Shulgin came to Australia to testify on behalf of the defense, to no avail.

2C-B is not specifically listed in the Australia Poisons Standard (October 2015), however similar drugs such as 2C-T-2 and 2C-I are making 2C-B fall under the Australian analogue act.<ref name="Poisons Standard">Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534</ref>

Belgium

In Belgium, 2C-B is a controlled substance making production, distribution, and possession illegal.

Brazil

In Brazil, 2C-B is a controlled substance making production, distribution, and possession illegal.

Canada

In Canada, 2C-B is classified under Controlled Drugs and Substances Act as Schedule III as "4-bromo-2,5-dimethoxybenzeneethanamine and any salt, isomer or salt of isomer thereof".<ref>Template:Cite web</ref>

2C-B has been rescheduled (Schedule III), in a new amendment, taking effect on October 31, 2016. This is to include the other 2C-x analogues.<ref>Template:Cite web</ref>

Chile

In August 2007, 2C-B, along with many other psychologically active substances,<ref>Template:Cite web</ref> was added to Ley 20.000, known as the Ley de drogas.

Czech Republic

Possession of more than 200Template:Nbspmg of 2C-B is punishable with a two years jail sentence.<ref>Template:Cite web</ref> Smaller amount is punishable by a fine. The 200Template:Nbspmg threshold is merely a guideline which the court can reconsider depending on circumstances.

Denmark

In Denmark, 2C-B is listed as a category B drug.<ref name="danish order on drugs">Template:Cite web</ref>

Estonia

In Estonia, 2C-B is classified as Schedule I.

Finland

Scheduled in the "government decree on substances, preparations and plants considered to be narcotic drugs".<ref>Template:Cite web</ref>

Germany

In Germany, 2C-B is controlled in the Betäubungsmittelgesetz (BtMG) Anlage I as "Bromdimethoxyphenethylamin" (BDMPEA).

Italy

2C-B is schedule I (tabella I).<ref>Template:Cite web</ref>

Japan

In Japan, 2C-B was scheduled in 1998. It was previously marketed as "Performax".

Luxembourg

In Luxembourg, 2C-B is a prohibited substance since 2001.<ref>Règlement grand-ducal du 14 décembre 2001 modifiant l'annexe du règlement grand-ducal modifié du 4 mars 1974 concernant certaines substances toxiques.</ref>

Netherlands

In the Netherlands, 2C-B was scheduled on July 9, 1997.

In the Netherlands, 2C-B became a list I substance of the Opium Law despite no health incidents occurring. Following the ban, other phenethylamines were sold in place of 2C-B until the Netherlands became the first country in the world to ban 2C-I, 2C-T-2 and 2C-T-7 alongside 2C-B.

Norway

In Norway, 2C-B was classified as Schedule II on March 22, 2004, listed as 4-bromo-2,5-dimethoxyphenethylamine.<ref>Template:Cite web</ref>

Poland

2C-B is schedule I (I-P group) in Poland.

Russia

Banned as a narcotic drug with a criminal penalty for possession of at least 10Template:Nbspmg.<ref>Template:Cite web</ref>

Spain

In Spain, 2C-B was added to Category 2 prohibited substances in 2002.

Sweden

2C-B is currently classified as Schedule I in Sweden.

2C-B was first classified as "health hazard" under the act Template:Lang (Act on the Prohibition of Certain Goods Dangerous to Health) as of April 1, 1999, under SFS 1999:58<ref name='Sweden 1999:58'>Template:Cite web</ref> that made it illegal to sell or possess. Then it became schedule I as of June 1, 2002, published in LVFS 2002:4<ref>Template:Cite web</ref> but mislabeled "2-CB" in the document. However, this was corrected in a new document, LVFS 2009:22<ref>Template:Cite web</ref> effective December 9, 2009.

Switzerland

In Switzerland, 2C-B is listed in Anhang D of the DetMV and is illegal to possess.<ref>Template:Cite web</ref>

United Kingdom

All drugs in the 2C family are Class A under the Misuse of Drugs Act which means they are illegal to produce, supply or possess. Possession carries a maximum sentence of seven years imprisonment while supply is punishable by life imprisonment and an unlimited fine.<ref name="talk_to_frank_law_uk">Template:Cite web</ref>

United States

In the United States, 2C-B is classified as a Schedule I controlled substance. This became permanent law on June 2, 1995,<ref name="fed_reg_1995">Template:Cite web</ref> following a proposal by the Drug Enforcement Administration in December 1994.<ref name="fed_reg_1994">Template:Cite web</ref>

Research

2C-B has been studied and suggested for more widespread use in psychedelic-assisted psychotherapy.<ref name="SessaFischer2016" /><ref name="Mallaroni_2023" /><ref name="Shulgin_1975" /><ref name="Dean_2013" />

See also

• 2C (psychedelics)
• Stimulant § Serotonin 5-HT_2A receptor agonists

External links

• 2C-B - Isomer Design
• 2C-B - PsychonautWiki
• 2C-B - Erowid
• 2C-B - PiHKAL - Erowid
• 2C-B - PiHKAL - Isomer Design
• 2C-B - The Shulgin Index
• The Big & Dandy 2C-B Thread - Bluelight
• Forgotten Psychedelics: What Is 2C-B? - Psychedelic Spotlight
• Is 2C-B a Psychedelic Drug? - Psychedelic Science Review (PSR)
• 2C-B: Effects, Dosage, & Safety - Tripsitter
• 2C-B - TripSit
• 2C-B – Graceful, Erotic, and Sensual? - HealingMaps
• 2C-B: If LSD and MDMA had a baby - PsychedelicHealth
• 2C-B Is the Drug Taking Over the UK’s Clubs - Vice